Clinical Trial Update: Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19 [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for CYNK-001 natural killer cell infusions in adults with COVID-19, spanning Phase 1 and Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronavirus Disease 2019
• Pneumonia
• Respiratory Tract Infections

Drugs mentioned

• CYNK-001

Snippet

Sponsor: Celularity Incorporated | Conditions: Coronavirus, Coronavirus Infection | Phase 1, Phase 2 | Status: UNKNOWN